News & Media
Newsroom
SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ Paves the Way to Launch its Second Innovative Drug Directly in the U.S.
8.26.2026
Full Release
SK Biopharmaceuticals Partially Resolves U.S. Patent Litigation Through Settlement with Generic Developer of XCOPRI
08.19.2026
Full Release
SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
06.15.2026
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate brochure
For more information about epilepsy, please download this infographic
To view the Hope, Hesitancy, and Hard Truths survey report, please click here.
Please see report infographic below
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd, and both are part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 12 compounds under clinical development